Condition: Ocular Graft Versus Host Disease · Sponsor: Lubris Bio Pty Ltd
An 84-day, prospective, randomized (1:1) vehicle controlled, double-masked pre-market, crossover study. Subjects with moderate to severe oGVHD related Dry Eye Disease Each subject will receive both treatments in random sequence, each for 28 days, separated by a 14-day vehicle washout period.
This description comes directly from the study's public registry record.
Edward CEO · 6193394016 · ertruitt@lubris.net
Always discuss trial participation with your own doctor first.
| Sydney Eye Hospital | Sydney, New South Wales, Australia | Not Yet Recruiting |
| OTA | Brisbane, Queensland, Australia | Recruiting |
| Royal Melbourne Hospital | Melbourne, Victoria, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07118254